Workflow
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
Olema PharmaceuticalsOlema Pharmaceuticals(US:OLMA) Newsfilterยท2025-04-25 17:00

Core Insights - Olema Pharmaceuticals announced preclinical data for OP-3136, a novel small molecule that selectively inhibits KAT6, demonstrating anti-tumor activity in prostate, ovarian, and non-small cell lung cancer models [1][2][5] Group 1: OP-3136 Overview - OP-3136 is an orally available small molecule that targets KAT6, an epigenetic factor involved in various cancers, including breast cancer [4][7] - The Investigational New Drug (IND) application for OP-3136 was approved by the FDA in December 2024, and patient recruitment for the Phase 1 trial is currently ongoing [4][5] Group 2: Preclinical Findings - In preclinical studies, OP-3136 exhibited significant anti-proliferative activity in ER+ breast cancer models and showed robust tumor growth inhibition in ovarian cancer models [4][6] - OP-3136 demonstrated sustained tumor regression in the OVCAR3 ovarian cancer model over a 28-day study period [6] - In the LCLC-97TM1 NSCLC model, OP-3136's tumor growth inhibition was comparable to ribociclib, and the combination of both showed enhanced anti-tumor activity [6] - The 22Rv1 prostate cancer model showed dose-dependent tumor growth inhibition with OP-3136, and when combined with docetaxel, it resulted in improved anti-tumor effects [6] Group 3: Clinical Development - Olema is actively recruiting patients for the Phase 1 trial of OP-3136, exploring its potential as a monotherapy and in combination regimens across multiple solid tumor types [2][5] - The data on OP-3136 will be presented at the 2025 AACR Annual Meeting, highlighting its potential utility in treating challenging cancers beyond breast cancer [5][6]